Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.

Abstract: The disclosure relates to an apparatus and method for liquid cooling of an electronic component. A housing includes an insertion slot and defines at least one component chamber for carrying the electronic component. A fluid inlet and fluid outlet are provided on the housing. A liquid coolant circuit passes through the housing at least from the inlet to the outlet.

Abstract: Described herein are systems, methods, and computer readable media for performing data conversion on sensor data to obtain modified sensor data that is formatted/structured appropriately for downstream processes that rely on the sensor data as input. The sensor data can include point cloud data captured by a LiDAR, for example. A grid structure and corresponding grid characteristics can be determined and the sensor data can be converted to grid-based sensor data by associating the grid structure and its characteristics with the sensor data. Generating the grid-based sensor data can include reformatting the point cloud data to superimpose the grid structure and its grid characteristics onto the point cloud data. Various downstream processing that cannot feasibly be performed on the raw sensor data can then be performed efficiently on the modified grid-based sensor data by virtue of the grid structure imbuing the sensor data with spatial proximity information.

Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for preventing graft rejection in solid organ transplantation, by employing anti-CD40 antibodies.

Abstract: The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.

Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.

Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating T1DM, by employing anti-CD40 antibodies.

Abstract: Described herein are systems, methods, and computer readable media for performing data conversion on sensor data to obtain modified sensor data that is formatted/structured appropriately for downstream processes that rely on the sensor data as input. The sensor data can include point cloud data captured by a LiDAR, for example. A grid structure and corresponding grid characteristics can be determined and the sensor data can be converted to grid-based sensor data by associating the grid structure and its characteristics with the sensor data. Generating the grid-based sensor data can include reformatting the point cloud data to superimpose the grid structure and its grid characteristics onto the point cloud data. Various downstream processing that cannot feasibly be performed on the raw sensor data can then be performed efficiently on the modified grid-based sensor data by virtue of the grid structure imbuing the sensor data with spatial proximity information.

Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating hidradenitis suppurativa, by employing CD40 antagonists, such as anti-CD40 antibodies.

Abstract: Described herein are systems, methods, and computer readable media for performing data conversion on sensor data to obtain modified sensor data that is formatted/structured appropriately for downstream processes that rely on the sensor data as input. The sensor data can include point cloud data captured by a LiDAR, for example. A grid structure and corresponding grid characteristics can be determined and the sensor data can be converted to grid-based sensor data by associating the grid structure and its characteristics with the sensor data. Generating the grid-based sensor data can include reformatting the point cloud data to superimpose the grid structure and its grid characteristics onto the point cloud data. Various downstream processing that cannot feasibly be performed on the raw sensor data can then be performed efficiently on the modified grid-based sensor data by virtue of the grid structure imbuing the sensor data with spatial proximity information.

Abstract: Described herein are systems, methods, and computer readable media for performing data conversion on sensor data to obtain modified sensor data that is formatted/structured appropriately for downstream processes that rely on the sensor data as input. The sensor data can include point cloud data captured by a LiDAR, for example. A grid structure and corresponding grid characteristics can be determined and the sensor data can be converted to grid-based sensor data by associating the grid structure and its characteristics with the sensor data. Generating the grid-based sensor data can include reformatting the point cloud data to superimpose the grid structure and its grid characteristics onto the point cloud data. Various downstream processing that cannot feasibly be performed on the raw sensor data can then be performed efficiently on the modified grid-based sensor data by virtue of the grid structure imbuing the sensor data with spatial proximity information.

Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.

Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for preventing graft rejection in solid organ transplantation, by employing anti-CD40 antibodies.

Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.

Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.

Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating Sjögren's syndrome, by employing anti-CD40 antibodies.

Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.

Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.

Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.

Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.